The United Laboratories International Holdings (HK:3933) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The United Laboratories International Holdings Limited has successfully enrolled the first subject in their Phase IIa clinical trial in China for TUL12101 Eye Drops, aiming to treat dry eye syndrome. This follows positive Phase I trial results, indicating good safety and tolerability of the drops. The company, a pioneer in developing RASP inhibitors in China, is looking to strengthen its position in the ophthalmic drug market.
For further insights into HK:3933 stock, check out TipRanks’ Stock Analysis page.